HC Wainwright Has Bearish Estimate for CAPR FY2026 Earnings

Key Points

• HC Wainwright trimmed its FY2026 EPS estimate for Capricor Therapeutics to a loss of $2.76 per share from a loss of $2.75, while maintaining a Neutral rating.
• Capricor reported a quarterly loss of $0.73 per share, missing analysts’ consensus estimate of a $0.44 loss by $0.29.
• Analyst views are mixed: five rate the stock Buy, five Hold, and one Sell; MarketBeat reports a consensus Hold rating and a $29.77 target price.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - HC Wainwright lowered their FY2026 EPS estimates for Capricor Therapeutics in a report issued on Wednesday, November 11th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($2.76) per share for the year, down from their previous forecast of ($2.75). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Capricor Therapeutics' current full-year earnings is ($1.71) per share.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.29).

Several other equities analysts also recently commented on CAPR. Wall Street Zen downgraded shares of Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Alliance Global Partners lowered shares of Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 target price for the company. in a report on Tuesday, July 28th. JonesTrading raised Capricor Therapeutics from a "hold" rating to a "buy" rating and set a $25.00 target price on the stock in a research note on Wednesday. Oppenheimer restated an "outperform" rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Finally, B. Riley Financial raised Capricor Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $5.00 to $21.00 in a research report on Monday, September 14th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $29.77.

Capricor Therapeutics Price Performance

Shares of Capricor Therapeutics stock opened at $10.24 on Friday. Capricor Therapeutics has a 12-month low of $2.96 and a 12-month high of $40.37. The company's fifty day simple moving average is $8.10 and its two-hundred day simple moving average is $19.92.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Walleye Capital LLC bought a new position in Capricor Therapeutics in the 1st quarter worth $5,397,000. Bank of America Corp DE boosted its stake in shares of Capricor Therapeutics by 672.0% during the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company's stock valued at $12,631,000 after purchasing an additional 361,664 shares in the last quarter. Montanova Capital LLC boosted its stake in shares of Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company's stock valued at $98,554,000 after purchasing an additional 274,184 shares in the last quarter. Ally Bridge Group NY LLC bought a new stake in shares of Capricor Therapeutics during the 1st quarter valued at about $3,463,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Capricor Therapeutics during the second quarter valued at about $3,895,000. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company's leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.